ATS
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Personal Folders
Right arrow Download to citation manager
Right arrow Author home page(s):
Eugene A. Grossi
Right arrow Permission Requests
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Grossi, E. A.
Right arrow Articles by LaPietra, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Grossi, E. A.
Right arrow Articles by LaPietra, A.
Related Collections
Right arrowRelated Article

Ann Thorac Surg 2000;70:335
© 2000 The Society of Thoracic Surgeons

Correspondence

Heparin coating of bypass systems

Eugene A. Grossi, MDa, Christopher Derivaux, MDa, Angelo LaPietra, MDa

a Cardiovascular Research Laboratory, New York University School of Medicine, 530 First Ave, Suite 9V, New York, NY 10016, USA

To the Editor

The article "IL-6 and IL-8 Levels After Cardiopulmonary Bypass Are Not Affected by Surface Coating" by Horton and colleagues [1] presents data that question several published studies regarding the salutary effect of heparin-coated bypass circuits on the reduction of serum interleukins during cardiopulmonary bypass [2]. Close review of the methodology used is necessary to help us interpret these results. It is important to point out that the cardiopulmonary bypass circuits used by the authors were heparin-coated oxygenators only, not tip-to-tip coated systems as in the study by Schreurs and associates [3]. This study demonstrated a decrease in pediatric inflammatory markers (soluble E-selection and ß-thromboglobulin) associated with heparin-bonded systems. The design of the study by Horton and co-workers is similar to that of the study by Ashraf and coauthors [4], where heparin coating was used on the oxygenators only. That report demonstrated no significant difference in interleukin levels, which were measured only after and not during CPB, but did show a decrease in the inflammatory marker elastase associated with the heparin bonding. In addition, 94% of the patients in the report by Horton and associates received whole blood as part of the circuit priming, and certainly this could have provided an exogenous source of or stimulation for the interleukin response [5], which could mitigate the effect of heparin bonding.

References

  1. Horton S.B., Butt W.W., Mullaly R.J., et al. IL-6 and IL-5 levels after cardiopulmonary bypass are not affected by surface coating. Ann Thorac Surg 1999;68:1751-1755.[Abstract/Free Full Text]
  2. Weerwind P.W., Maessen J.G., van Tits L.J., et al. Influence of Duraflo II heparin-treated extracorporeal circuits on the systemic inflammatory response in patients having coronary bypass. J Thorac Cardiovasc Surg 1995;110:1633-1641.[Abstract/Free Full Text]
  3. Schreurs H.H., Wijers M.J., Gu Y.J., et al. Heparin-coated bypass circuits. Ann Thorac Surg 1998;66:166-171.[Abstract/Free Full Text]
  4. Ashraf S., Tian Y., Cowan D., Entress A., Martin P.G., Watterson K.G. Release of proinflammatory cytokines during pediatric cardiopulmonary bypass. Ann Thorac Surg 1997;64:1790-1794.[Abstract/Free Full Text]
  5. Weisbach V., Wanke C., Zingsem J., Zimmermann R., Eckstein R. Cytokine generation in whole blood, leukocyte-depleted and temporarily warmed red blood cell concentrates. Vox Sang 1999;76:100-106.[Medline]

Related Article

Reply
Tom R. Karl and Stephen B. Horton
Ann. Thorac. Surg. 2000 70: 335. [Extract] [Full Text] [PDF]



This article has been cited by other articles:


Home page
 Eur. J. Cardiothorac. Surg.Home page
N. Sadeghi, S. Sadeghi, and A. Karimi
Mitral valve recurrence of a left atrial myxoma
Eur. J. Cardiothorac. Surg., March 1, 2002; 21(3): 568 - 573.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Personal Folders
Right arrow Download to citation manager
Right arrow Author home page(s):
Eugene A. Grossi
Right arrow Permission Requests
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Grossi, E. A.
Right arrow Articles by LaPietra, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Grossi, E. A.
Right arrow Articles by LaPietra, A.
Related Collections
Right arrowRelated Article

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
ANN THORAC SURG ASIAN CARDIOVASC THORAC ANN EUR J CARDIOTHORAC SURG
J THORAC CARDIOVASC SURG ICVTS ALL CTSNet JOURNALS